Certificate pursuant to Regulation 74(5) of SEBI (Depositories and participants) Regulations, 2018.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has submitted a routine quarterly compliance certificate from its Registrar and Share Transfer Agent, Purva Sharegistry (India) Pvt. Ltd., for the quarter ended December 31, 2025. The certificate confirms that share certificates received for dematerialization during the October–December 2025 quarter were processed, accepted or rejected, and that the underlying shares were listed on the stock exchanges. The attached details show that a handful of shareholders converted small lots of physical shares into demat form — mostly 100-share blocks each from holders like Rahul Arun Jaggia, Morvarid Tafty, Mayur Jayraj Chauhan, Manish Shah, and Chandrakant L Gala. The filing was signed by Managing Director Fredun Nariman Medhora and submitted to BSE on January 13, 2026.
No material impact on shareholders or the stock price. This is a standard SEBI-mandated administrative disclosure confirming routine dematerialization activity; no business or financial information is conveyed.